Compare OPBK & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | MIST |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 176.3M |
| IPO Year | 2018 | 2019 |
| Metric | OPBK | MIST |
|---|---|---|
| Price | $14.18 | $1.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $8.00 |
| AVG Volume (30 Days) | 31.2K | ★ 3.0M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | ★ 23.74 | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $3,204,000.00 | N/A |
| Revenue This Year | $16.07 | $2,915.14 |
| Revenue Next Year | $11.60 | N/A |
| P/E Ratio | $8.24 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.57 | $1.00 |
| 52 Week High | $15.27 | $3.06 |
| Indicator | OPBK | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 59.26 |
| Support Level | $13.81 | $1.84 |
| Resistance Level | $14.35 | $2.06 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 78.70 | 68.04 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).